Raynaud's Phenomenon: Workup and Treatment
For first-line pharmacological treatment of Raynaud's phenomenon, use oral nifedipine (a dihydropyridine calcium channel blocker), and combine this with non-pharmacological measures including cold avoidance, use of gloves and heating devices, and avoidance of direct contact with cold surfaces 1, 2.
Diagnostic Workup
The critical question in evaluating Raynaud's phenomenon is distinguishing primary (idiopathic) from secondary RP, particularly identifying underlying systemic sclerosis (SSc) or other connective tissue diseases.
Essential Initial Investigations
Nailfold capillaroscopy: This is the gold standard for distinguishing primary from secondary RP 3, 4. Look for capillary abnormalities including dilated loops, hemorrhages, and capillary loss that suggest secondary RP.
Autoantibody testing: Check antinuclear antibodies (ANA) and SSc-specific antibodies to stratify risk of progression to systemic sclerosis. The VEDOSS project confirmed that autoantibodies combined with capillaroscopy findings effectively predict SSc development 4.
Basic imaging: Chest X-ray and hand X-rays to evaluate for underlying conditions 5.
Clinical Red Flags for Secondary RP
Look specifically for: asymmetric attacks, digital ulceration or tissue loss, abnormal capillaroscopy findings, positive autoantibodies, onset after age 30, and associated symptoms of connective tissue disease.
Treatment Algorithm
Non-Pharmacological Management (First-Line for All Patients)
Cold protection is essential 2:
- Use gloves and heating devices for hands (RCT evidence confirms gloves reduce RP burden)
- Avoid direct contact with cold surfaces
- Thoroughly dry skin after washing
- Avoid sudden temperature changes
- Smoking cessation is mandatory
- Avoid caffeine and drugs that interfere with vascular tone
Pharmacological Treatment
First-Line: Calcium Channel Blockers
Oral nifedipine (dihydropyridine-type CCB) should be initiated as first-line therapy 1. This recommendation is based on consistent evidence and remains unchanged in the most recent 2025 EULAR guidelines.
Second-Line: PDE5 Inhibitors
PDE5 inhibitors should be considered when CCBs are insufficient or not tolerated 1. A 2013 meta-analysis of 6 RCTs (224 patients) demonstrated:
- Improved Raynaud's condition score (mean difference −0.46, p=0.002)
- Reduced daily frequency of attacks (mean difference −0.49, p<0.0001)
- Decreased daily duration of attacks by 14.62 minutes (p<0.0001)
Third-Line: Intravenous Iloprost
For severe SSc-RP following failure of oral therapy, consider intravenous iloprost 1. This is particularly relevant for patients with critical ischemia or progressive digital ulceration.
Special Consideration: Digital Ulcer Prevention
For patients with systemic sclerosis at risk of digital ulcers, bosentan should be considered for reduction of new digital ulcer formation 1. This recommendation is specific to bosentan, not extended to the entire endothelin receptor antagonist class, as macitentan failed to show efficacy in two RCTs involving over 400 SSc patients.
Important caveat: Oral treprostinil failed to demonstrate efficacy in digital ulcer healing and prevention in recent RCT data 1.
Common Pitfalls to Avoid
Do not assume all RP is benign: Always perform capillaroscopy and autoantibody testing to identify secondary causes, particularly SSc, which requires different management.
Do not use macitentan for digital ulcer prevention: Despite being in the same drug class as bosentan, it has negative RCT evidence 1.
Do not overlook non-pharmacological interventions: These are evidence-based (Level 2 evidence) and should be implemented in all patients, not just as an afterthought 2.
Do not delay escalation in severe cases: If patients develop digital ulceration or critical ischemia despite oral therapy, move to intravenous prostacyclin therapy rather than continuing ineffective oral regimens.
Treatment Escalation Strategy
- Initiate: Nifedipine + non-pharmacological measures
- Add or switch: PDE5 inhibitor if inadequate response
- Escalate: IV iloprost for severe/refractory cases
- Consider: Bosentan specifically for SSc patients with recurrent digital ulcers
The 2025 EULAR guidelines 1 represent the highest quality, most recent evidence and should guide your management approach, supplemented by the non-pharmacological recommendations from the 2024 EULAR guidelines 2.